MINNEAPOLIS--(BUSINESS WIRE)--VigiLanz, a digital healthcare intelligence firm, today announced that its new business intelligence and predictive analytics software-as-a-service (SaaS) platform is demonstrating significantly positive results since its introduction in October 2015. The company is demonstrating its SaaS platform at the HIMSS annual information technology conference and exhibit at its booth #12306 in Las Vegas between February 29th and March 3rd.
VigiLanz’ business intelligence (BI) is an innovative clinical SaaS service designed to provide real-time predictive insights to optimize clinical interventions and outcomes, reduce medical errors, lower patient readmission risk, identify hotspot disease trends and improve population health. VigiLanz’ BI suite is engineered to integrate and complement VigiLanz’ real-time Clinical Intelligence and Surveillance services that today support nearly 400 hospitals in the U.S.
“The VigiLanz BI platform and our Temporalytics® predictive analytics model is actively being tested for the early identification of patients at high risk for sepsis, and is demonstrating strong initial results in sensitivity, specificity and positive predictive value,” said David Goldsteen M.D., VigiLanz CEO and Chairman. “Based on our performance to date, we continue to believe in our contribution to helping transform health care through a real time, integrated clinical and business intelligence platform that can impact patient care and outcomes beyond current methodologies, by delivering better, more timely decision-making support and intelligence.”
Dr. Goldsteen said trials comparing VigiLanz’ Temporalytics models with the standard or modified SIRS criteria for early identification of severely septic patients are, “in the initial phases, demonstrating positive predictive value increase of well over a two-fold factor along with meaningful improvements in both sensitivity and specificity, without adversely impacting false-negative patient diagnoses rates.”
Dr. Goldsteen said VigiLanz’ BI suite and Temporalytics models can be applied to combat many other significant clinical issues such as glycemic control, and risk associated with falls, deep-vein thrombosis, length-of-stay and readmissions. Dr. Goldsteen said that one of the compelling benefits of Temporalytics is the ability to integrate valuable predictive insights with the company’s numerous real-time clinical intelligence SaaS services that ingest and normalize disparate system data from the hospital EHR that inform decision making when most needed. He said this data is interfaced, real-time, with highly robust, exception-based, temporal rules, predictive algorithms, and events to deliver immediate clinical and business intelligence information and metadata. These resulting actionable insights can be delivered within the VigiLanz workflow, or as part of any hospital interoperable enterprise system workflow.
About VigiLanz
VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing digital health care firm. The company is a leading provider of SaaS health care intelligence and predictive analytics. VigiLanz ’real-time enterprise intelligence resources (EIR) platform is capable of aggregating disparate health system EHR transactional workflow and documentation data to identify real-time clinical issues and avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. The company was founded by David Goldsteen, M.D. and David Klass, M.D. in 2001. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the 21st century vision for real-time health care by delivering the right data, to the right people, at the right time and improving patient care and operational effectiveness.
